Difference between revisions of "Volasertib (BI-6727)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - " (NCT[0-9]{8})" to " https://clinicaltrials.gov/ct2/show/$1") |
Warner-admin (talk | contribs) |
||
| Line 17: | Line 17: | ||
[[Category:Acute myeloid leukemia medications (investigational)]] | [[Category:Acute myeloid leukemia medications (investigational)]] | ||
| − | |||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 01:03, 15 June 2023
Mechanism of action
Polo-like kinase 1 (PLK1) inhibitor
Preliminary data
Acute myeloid leukemia
- BI 1230.4: Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood. 2014 Aug 28;124(9):1426-33. Epub 2014 Jul 8. link to original article link to PMC article PubMed https://clinicaltrials.gov/ct2/show/NCT00804856
Also known as
- Code name: BI 6727